Table 3 Review of the literature on modality of KRT for TLS
Author/year reference No | No of cases | Age (years) | Tumor type | Maximum LDH in cases (IU/L) | Modality of KRT (membrane) | KRT target |
|---|---|---|---|---|---|---|
Saccente SL/1995 [14] | 5 | 1–12 | BL (N = 3), ALL (N = 2) | 10,056 | CVVH (Polysulfone) | Metabolic derangement |
Choi KA/2009 [15] | 11 | 34–63 | BL (N = 11) | 25,900 | CVVH (Not available) | Metabolic derangement |
Nakamura M/2009 [16] | 4 | 19–68 | ML (N = 2), ALL (N = 1), AML (N = 1) | 32,820 | CVVHDF (Polymethyl methacrylate) | Cytokines |
Wang Y/2018 [17] | 8 | 5–14 | ALL (N = 5), NHL (N = 2), BL (N = 1) | Not available | CVVH daytime (Acrylonitrile) | Metabolic derangement |